Aimovig 70mg prefilled syringes are called Suviray internationally.
We are not shipping this product at this time.
Surivay/Amovig are manufactured at:
Amgen Manufacturing Ltd, State Road 31,Km 24.6, Juncos 00777-4060, PUERTO RICO USA
Information about Suviray (Erenumab)
Suviray is a brand name for Erenumab, a medication used primarily for the prevention of migraine headaches in adults. It is categorized as a CGRP (calcitonin gene-related peptide) receptor antagonist. Erenumab is a monoclonal antibody that works by targeting the CGRP receptor, which plays a role in the initiation and maintenance of migraines.
Product Highlights
- For preventing chronic and episodic migraines in adults. It is used for patients who experience frequent migraines, reducing both the number and severity of migraine attacks.
- Particularly for individuals who have 15 or more headache days per month, with at least 8 of those days characterized by migraine-like symptoms.
Key Ingredient
Key Benefits
- Proven to reduce the number of days a person experiences a migraine each month.
- By preventing migraines, patients may experience a significant improvement in overall quality of life, with fewer days of disability due to headaches.
- Erenumab has been shown to be effective for both chronic migraine sufferers (more than 15 headache days a month) and episodic migraine sufferers (less than 15 headache days a month).
- Many patients report fewer or more manageable side effects compared to traditional migraine treatments like oral medications.
Direction of Use
- Suviray (Erenumab) is given through a subcutaneous injection, usually once a month.
- The drug can be self-administered by patients after proper training, using a prefilled syringe or an auto-injector pen.
- The usual starting dose is 70 mg once a month, although it can be increased to 140 mg monthly if necessary, depending on the patient's response.
Safety Concerns
- Some of the most common side effects of Suviray (Erenumab) include injection site reactions (such as pain, redness, or swelling), constipation, and possible allergic reactions.
- Rare but serious side effects may include severe allergic reactions (anaphylaxis), trouble breathing, or a rash.
- Caution should be taken for patients with a history of hypersensitivity to the drug or any of its components.
Avoid Suviray (Erenumab) If
- If you have a known hypersensitivity to Erenumab or any of the ingredients in Suviray, you should not use this medication.
- Patients with severe liver disease may need to avoid this medication or discuss its use with their healthcare provider.
- The safety of Suviray during pregnancy or breastfeeding has not been well established. It is generally recommended to avoid use unless the potential benefits outweigh the risks.
- Suviray is not recommended for individuals under 18 years of age, as its safety and efficacy in children have not been established.
This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.
